Main research purposes:~To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.~Secondary research purposes:~To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory CD7+ hemolymphoid malignancies.~Exploratory research purpose：~To explore the immunogenicity of SENL101；~T cell NK cell recovery time after treatment；~Other indicators of interest to researchers。
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.